Pall T. Onundarson: Questioning the Dogma of VKA Management
Pall T. Onundarson, Professor Emeritus at Landspitali University Hospital, shared Edward Lee Carter‘s post on LinkedIn:
”Fortunately, there are people such as Edward Lee Carter that are willing to question the dogma in VKA management – and that warfarin management and outcomes can be fiixed…by replacing the old prothrombin time with a more appropriate test.”
Edward Lee Carter, Clinical Pharmacist Practitioner at U.S. Department of Veterans Affairs, shared a post on LinkedIn:
”Did the arrival of DOACs unintentionally end innovation in warfarin management?
That question has been on my mind recently.
Over the past decade, anticoagulation research has understandably focused on DOACs.
They have transformed care for millions of patients and represent one of the greatest advances in cardiovascular medicine.
But while our attention shifted to developing better drugs…
Did we stop trying to make warfarin itself better?
Warfarin hasn’t disappeared.
Millions of patients still depend on it because of:
- Mechanical heart valves
- Antiphospholipid syndrome
- Advanced kidney disease
- Cost considerations
- Drug interactions
- Other clinical situations where it remains the preferred therapy
Yet we continue to monitor it using PT/INR, a test developed nearly a century ago that was never designed specifically to measure warfarin’s pharmacodynamic effect.
That is where the work of Professor Emeritus of Hematology Dr. Pall T. Onundarson, M.D. deserves another look.
His research, together with colleagues studying Fiix-guided monitoring, asked a simple but important question:
If we can improve the way we monitor warfarin, can we improve patient outcomes without changing the drug itself?
The randomized Fiix trial suggested that monitoring Factors II and X while minimizing the influence of Factor VII reduced thromboembolic events without increasing major bleeding.
Subsequent observational studies from Iceland have continued to support that concept, although broader independent validation is still needed before widespread adoption.
Whether Fiix ultimately becomes the future is almost beside the point.
The bigger question is this:
Why did innovation in warfarin monitoring largely slow once DOACs arrived?
Innovation isn’t always inventing a new medication.
Sometimes it’s questioning long-held assumptions.
Sometimes it’s improving the care of patients who still rely on therapies we already have.
As pharmacists, physicians, laboratorians, and researchers, perhaps we should ask ourselves:
Are we comparing DOACs to the best version of warfarin…or simply the version we’ve always used?
I’d love to hear perspectives from clinicians, laboratorians, and researchers.
Is it time to reopen the conversation around warfarin monitoring?”

Stay updated with Hemostasis Today.
-
Nov 18, 2026, 13:34Vincenzo De Angelis: Strengthening Plasma Management and Quality Control in Eastern Europe
-
Nov 18, 2026, 13:34Standardizing Bleeding Outcome Assessment in Hemophilia Clinical Trials – JTH
-
Nov 18, 2026, 13:34Nicolas Gendron: Towards Sustainable Anticoagulation
-
Nov 18, 2026, 13:33Breaking the Silence on Women and Girls with Bleeding Disorders – EHC
-
Nov 18, 2026, 13:32Maria Elisa Mancuso: Next-Generation Protein Therapies in Hemophilia
-
Nov 18, 2026, 13:25Maia Meier: Advocating for Women and Girls with Bleeding Disorders
-
Nov 18, 2026, 13:19Sjoerd Fabian Koopman: Exploring Tissue Distribution of Extended Half-Life Factor IX Concentrates
-
Nov 18, 2026, 13:16Ifeanyichukwu Ifechidere: Choosing Between Clot-Based and Chromogenic Coagulation Assays
-
Nov 18, 2026, 13:06Saurabh Mehta: Daily Iron Supplementation in Children and Adolescents